FDA Cracks Down on Firms Failing to Pay GDUFA Fees

The FDA has warned three generics makers for failing to pay GDUFA fees during the last three fiscal years.

The companies —Syntho Pharmaceuticals of Farmingdale, N.Y., Sharon Bio-Medicine of Dehradun, Uttarakhand in India, and Wuxi Kaili Pharmaceutical of Yixing City, Jiangsu in China — join 31 other companies the FDA has cited as being in arrears for at least one of the last three fiscal years, according to a July 7 updated arrears list.  

Under the 2012 Generic Drug User Fee Act, firms owe different fees depending on whether they are U.S. or foreign-based and what type of product they manufacture, either finished dosage form or active pharmaceutical ingredient.

Syntho and Sharon owe $643,258 and $688,258, respectively, for the three years, while Wuxi Kaili, an active pharmaceutical ingredient maker, owes $147,899.

Failure to pay means all products manufactured at the facilities are subject to seizure or injunction, the FDA notes in near-identical June 22 warning letters. Appearing on the arrears list also means ANDAs will be automatically denied. The foreign facilities also risk being placed on import alert, denying product entry into the U.S.

The three firms did not respond to a request for comment by press time.

Stay up to date on regulatory stories like this one by subscribing to the Drug GMP Report. For over 20 years, drug manufacturers have relied on DGR for the latest on FDA’s interpretation and enforcement of cGMPs and the Quality Systems Regulation — information you need to stay in compliance.